Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Employee Lawsuit Withdrawn, But Burrill Faces New Investor Claims

This article was originally published in Scrip

Executive Summary

A lawsuit filed by an employee who oversaw venture capital funds run by Steven Burrill has been dismissed, but a separate lawsuit filed against Burrill, a prominent San Francisco-based advisor to life science companies, has been amended with new accusations against the fund's auditor, PricewaterhouseCoopers (PwC).

You may also be interested in...

Once-Trusted Investment Advisor Burrill Faces Criminal Fraud Charges

A federal grand jury indicted Steven Burrill and an associate on charges of fraud and tax evasion regarding investment funds run by the San Francisco-based life science advisor, who settled a related SEC claim in 2016. If convicted, he could spend decades in prison and pay millions in fines.

Finance Watch: Investors Bet Billions On Big Biopharma Offerings

Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.

Sunovion Plans September Launch For Parkinson’s 'Off' Episode Drug Kynmobi

Kynmobi is an important approval for parent company Sumitomo Dainippon ahead of the loss of exclusivity for Latuda. Sunovion hopes to launch after COVID-19 social distancing requirements ease.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts